

Evaluation of NBI-1117570 in adults with stable schizophrenia

Submission date 09/04/2026	Recruitment status Recruiting	☒ Prospectively registered
		☐ Protocol
Registration date 10/04/2026	Overall study status Deferred	☐ Statistical analysis plan
		☐ Results
Last Edited 10/04/2026	Condition category Mental and Behavioural Disorders	☐ Individual participant data
		☒ Record updated in last year

Plain English summary of protocol

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Contact information

Type(s)

Principal investigator

Contact name

Dr Jorg Taubel

ORCID ID

<https://orcid.org/0000-0002-0010-207X>

Contact details

1A Newcomen Street, London Bridge
London
United Kingdom
SE1 1YR
+44 20 7042 5800
j.taubel@richmondpharmacology.com

Type(s)

Scientific, Public

Contact name

Mr Clinical Development Lead

Contact details

Neurocrine Biosciences, Inc.
6027 Edgewood Bend Court
San Diego
United States of America
CA 92130
+1-877-641-3461
medinfo@neurocrine.com

Additional identifiers

Integrated Research Application System (IRAS)
1013028

Study information

Scientific Title

A phase 1b, single-center, open-label, intra-participant rising dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of NBI-1117570 monotherapy in adults with stable schizophrenia

Study objectives

Ethics approval required

Ethics approval required

Ethics approval(s)

Approved 17/03/2026, London – London Bridge (2 Redman Place Stratford, London, E20 1JQ, United Kingdom; +44 207 104 8229; londonbridge.rec@hra.nhs.uk), ref: 26/LO/0002

Primary study design

Interventional

Allocation

N/A: single arm study

Masking

Open (masking not used)

Control

Uncontrolled

Assignment

Sequential

Purpose

Treatment

Study type(s)

Health condition(s) or problem(s) studied

Schizophrenia

Interventions

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Intervention Type

Drug

Phase

Phase I

Drug/device/biological/vaccine name(s)

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Primary outcome(s)

1. - measured using - at -

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Key secondary outcome(s)**Completion date**

31/12/2027

Eligibility**Key inclusion criteria**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 Years

Upper age limit

55 Years

Sex

All

Total final enrolment

0

Key exclusion criteria

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Date of first enrolment

13/04/2026

Date of final enrolment

30/09/2027

Locations**Countries of recruitment**

United Kingdom

England

Study participating centre

Richmond Pharmacology Limited

1A Newcomen Street

London

England

SE1 1YR

Sponsor information**Organisation**

Neurocrine Biosciences (United States)

ROR

<https://ror.org/05d84mm26>

Funder(s)

Funder type

Funder Name

Neurocrine Biosciences

Alternative Name(s)

Neurocrine Biosciences, Inc.

Funding Body Type

Government organisation

Funding Body Subtype

For-profit companies (industry)

Location

United States of America

Results and Publications

Individual participant data (IPD) sharing plan**IPD sharing plan summary**

Not expected to be made available